Linkage and Association Studies of Prostate Cancer Susceptibility: Evidence for Linkage at 8p22-23  by Xu, Jianfeng et al.
Am. J. Hum. Genet. 69:341–350, 2001
341
Linkage and Association Studies of Prostate Cancer Susceptibility: Evidence
for Linkage at 8p22-23
Jianfeng Xu,1 Siqun L. Zheng,2 Gregory A. Hawkins,1 Dennis A. Faith,3 Brian Kelly,3
Sarah D. Isaacs,3 Kathleen E. Wiley,3 Bao-li Chang,2 Charles M. Ewing,3 Piroska Bujnovszky,3
John D. Carpten,4 Eugene R. Bleecker,1 Patrick C. Walsh,3 Jeffrey M. Trent,4
Deborah A. Meyers,1 and William B. Isaacs3
1Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC; 2University of Maryland School of Medicine,
and 3Department of Urology, Johns Hopkins Medical Institutions, Baltimore; and 4National Human Genome Research Institute, National
Institutes of Health, Bethesda, MD
Multiple lines of evidence have implicated the short arm of chromosome 8 as harboring genes important in prostate
carcinogenesis. Although most of this evidence comes from the identification of frequent somatic alterations of 8p
loci in prostate cancer cells (e.g., loss of heterozygosity), studies have also suggested a role for 8p genes in mediation
of inherited susceptibility to prostate cancer. To further examine this latter possibility, we performed linkage analyses,
in 159 pedigrees affected by hereditary prostate cancer (HPC), using 24 markers on the short arm of chromosome
8. In the complete set of families, evidence for prostate cancer linkage was found at 8p22-23, with a peak HLOD
of 1.84 ( ), and an estimate of the proportion of families linked (a) of 0.14, at D8S1130. In the 79 familiesPp .004
with average age at diagnosis 165 years, an allele-sharing LOD score of 2.64 ( ) was observed, and sixPp .0005
markers spanning a distance of 10 cM had LOD scores 12.0. Interestingly, the small number of Ashkenazi Jewish
pedigrees ( ) analyzed in this study contributed disproportionately to this linkage. Mutation screening innp 11
HPC probands and association analyses in case subjects (a group that includes HPC probands and unrelated case
subjects) and unaffected control subjects were carried out for the putative prostate cancer–susceptibility gene, PG1,
previously localized to the 8p22-23 region. No statistical differences in the allele, genotype, or haplotype frequencies
of the SNPs or other sequence variants in the PG1 gene were observed between case and control subjects. However,
case subjects demonstrated a trend toward higher homozygous rates of less-frequent alleles in all three PG1 SNPs,
and overtransmission of a PG1 variant to case subjects was observed. In summary, these results provide evidence
for the existence of a prostate cancer–susceptibility gene at 8p22-23. Evaluation of the PG1 gene and other candidate
genes in this area appears warranted.
Introduction
The short arm of chromosome 8, specifically 8p22-23,
may harbor a prostate cancer–susceptibility gene(s) for
the following reasons. First, multiple loci on 8p are the
sites of frequent loss of heterozygosity (LOH) in a variety
of human cancers, including prostate (Macoska et al.
1995; Bova et al. 1996; MacGrogan et al. 1996; Vocke
et al. 1996; Deubler et al. 1997; Prasad et al. 1998),
colon (Cunningham et al. 1993), breast (Chuaqui et al.
1995), ovarian (Cliby et al. 1993), liver (Emi et al. 1992),
lung (Wistuba et al. 1999), bladder (Knowles et al.
1993), and head and neck cancer (Ransom et al. 1996).
In prostate cancer, LOH for markers on 8p was found
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to be one of the most frequent somatic alterations, oc-
curring in 160% of prostate cancers (Cunningham et al.
1996), and multiple homozygous deletions have been
mapped to this chromosomal arm (Bova et al. 1996;
Prasad et al. 1998). In addition, alterations of cancer-
related genes in the region, such as LZTS1, have been
identified in prostate cancer specimens and cell lines
(Ishii et al. 1999).
Second, genomewide scans for prostate cancer–
susceptibility genes in pedigrees affected with hereditary
prostate cancer (HPC) have provided some evidence for
prostate cancer linkage on 8p (Smith et al. 1996; Gibbs
et al. 2000). In the 66 pedigrees affected by HPC as-
certained by our group (Smith et al. 1996), there were
positive linkage scores at 8p, with a two-point para-
metric LOD of 0.7 at D8S550, a multipoint LOD as-
suming heterogeneity (HLOD) of 0.81 ( ) and aPp .05
multipoint nonparametric linkage score (NPL) of 2.02
( ). Similarly, Gibbs et al. (2000) reported evi-Pp .02
dence for linkage at the marker D8S1106, ∼5 cM from
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the marker D8S550. The maximum multipoint NPL
score was 2.02 in 44 pedigrees with late age at onset
(66 years).
Third, a candidate prostate cancer–susceptibility gene
located at 8p22-23, PG1, was cloned by a haplotype-
based association study conducted by Geneset (Cohen
et al. 1999). In their study, a high-density array of bial-
lelic markers, around D8S262 and D8S277 in the 8p23
region, was used to build haplotypes in case and control
samples. By comparing 281 prostate cancer case sub-
jects with 130 unaffected control subjects ascertained
in France, they found significant differences in allele,
genotype, and haplotype frequencies of several SNPs in
the PG1 gene between case and control subjects. The
allele frequencies of G of SNP 477, T of SNP 99217,
and A of SNP 467 in case subjects (control subjects)
were 0.33 (0.24), 0.31 (0.23), and 0.26 (0.16), respec-
tively, in their study. In their study, the haplotype fre-
quencies of G-T-A for the three SNPs were 0.25 and
0.13 in case and control subjects, respectively, with an
odds ratio (OR) of 2.17 ( ). A single proteinPp .0002
sequence, designated as the PG1 gene, was identified in
this candidate region. The function of this gene is un-
known, and no follow-up studies have been presented.
We have three major objectives in the current study:
first, evaluate evidence for linkage at 8p22-23, using
densely spaced markers in 159 HPC families ascertained
at Johns Hopkins Hospital; second, evaluate evidence
for association in the PG1 region using both the family-
based approach in the 159 HPC families and the case-
control approach in 249 case subjects with sporadic
prostate cancer and 211 unaffected male control sub-
jects; and third, screen the PG1 gene for segregating
mutations, using the single-strand conformation poly-
morphism (SSCP) method.
Methods
Family Collection
All 159 families with HPC were collected and studied
at the Brady Urology Institute at Johns Hopkins Hos-
pital in Baltimore. Families were ascertained from three
resources. A majority of them were ascertained through
referrals generated as a response to a letter by one of us
(P.C.W.) to 8,000 urologists throughout the country. The
second source was identified from family history records
of the patient population seen at Johns Hopkins Hos-
pital for treatment of prostate cancer. The remaining
families came from the respondents to articles published
in a variety of lay publications describing our studies of
families affected with prostate cancer. Prostate cancer
diagnosis was verified by medical records for each af-
fected man studied. Age at diagnosis of prostate cancer
was confirmed either through medical records or from
two other independent sources. The mean age at diag-
nosis was 64.3 years for the case subjects in these fam-
ilies. Of the families, 84% are non-Jewish whites, 6.9%
are Ashkenazi Jews, and 8.8% are black.
All 249 unrelated case subjects were recruited from
among patients who underwent treatment for prostate
cancer at the John Hopkins Hospital. The diagnosis of
prostate cancer for all these subjects was confirmed by
pathology reports. Preoperative prostate-specific antigen
(PSA) levels, Gleason score, and pathological stageswere
available for 92, 244, and 245 of the 249 case subjects,
respectively. Mean age at diagnosis for these case sub-
jects was 58.6 years (range 37–73 years, SD 6.85). Fam-
ily-history information was not obtained. Over 93% of
the case subjects are white, and 3.2% are black.
From among men participating in screening programs
for prostate cancer, 222 control subjects not affected
with prostate cancer were selected. By applying the ex-
clusion criteria of abnormal digital rectal examination
(DRE) and abnormal PSA level (i.e., 4 ng/ml), 211
were eligible for the study. The mean age at examination
was 58 years (range 40–80 years, SD 8.01). Of the el-
igible control subjects, 186% are white, and 7.1% are
black. On the basis of interviews of eligible control sub-
jects, 5.6% have a brother or father affected with pros-
tate cancer.
Marker Genotyping
Twenty-one microsatellite markers spanning ∼35 cM
at 8p22-23 were genotyped in 159 families with HPC.
These markers were selected from Marshfield compre-
hensive human genetic maps (Broman et al. 1998). Mul-
tiplex PCR, using fluorescently labeled primers (either
fam, hex, or ned), was performed, and the resulting PCR
fragments were separated using capillary electrophoresis
performed with an ABI 3700 sequencer. The genotypes
were scored using ABI software (GENOTYPER). A
modified version of the program Linkage Designer was
used to bin the alleles and check inheritance. The output
from Linkage Designer was then analyzed further for
any inconsistencies by running the LINKAGE software
(Lathrop et al. 1984; Cottingham et al. 1993) without
disease phenotype information. Marker allele frequen-
cies were estimated from the 214 independent individ-
uals in the data set (among them, 13 are Ashkenazi Jews
and 19 are black). The marker order and distances es-
timated from the data using CRIMAP (Lander and
Green 1987) were similar to the results in theMarshfield
database. Thus, the intermarker distances of the Marsh-
field database were used in the analyses.
Three SNPs in the PG1 gene were genotyped in all
159 HPC pedigrees, in the 249 unrelated case subjects
affected with prostate cancer, and in 211 unaffected con-
trol subjects. All information (e.g. sequence, nomencla-
ture, and designation of SNPs) for PG1 was obtained
from Cohen et al. (1999). SNP 477 (Cr G) is in intron
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Table 1
Primers Used for Mutation Screening of PG1 Exons
Exon Primer
Annealing
Temperature
(C)
1a-F GCCGAGCTGAGAAGATGCTG 62
1a-R CGGGAGCTCGGGTGGACGCC
1c-F CGCTGCCGCCGAGCTGAG 63
1c-R GGCTCACCTGGACCCCGG
2-F CAACATCATTCGTCAGTTTC 57
2-R ACCTAGGTTTCATGCAAATG
3-F CTGTGAAGAGCCTCATGTAC 62
3-R AGAGAGAAAAGCATGGAAAC
4-F CTGGCCAATTGTTATTTTAA 53
4-R AATTTAGAAACTGAGAGCTG
5-F ACCAAATTTGCTCTATGTCC 60
5-R AAAGTATCTTTTCCAGGAAG
6-F TTAATGACGGCACTGATTG 53
6-R AGGTGCGTGAACACACTTAC
7-F CTTTATATGACCATGAGTTC 46
7-R CTGGAACTGTTGTTACTCAC
8a-F CAGCGTGTAATAGCTACCTG 62
8a-R CACATACAGCTTCCTTCCAG
8c-F CCATCAATGTTGATCTTAAGTGG 50
8c-R AATGTAGCACATCCCACTGTCTG
3, SNP 99217 (CrT) is in intron 5, and SNP 467 (GrC)
is in the 3′ untranslated region. Marker D8S561 is an
intragenic marker. Direct sequencing of PCR products
was used to genotype the three SNPs. All the PCRs were
performed in a 10-ml volume consisting of 30 ng genomic
DNA, 0.2 mM each primer, 0.2 mM each dNTP, 1.5 mM
MgCl2, 20 mM Tris-HCl, 50 mM KCl, and 0.5 U Taq
polymerase (Life Technologies). The primers for the SNP
477 were 5′-TGTTGATTTACAGGCGGC-3′ and 5′-
GGAAAGGTACTCATTCATAG-3′. The primers for the
SNP 99217 were 5′-GGTGGGAATTTACTATATG-3′
and 5′-GTTTATTTTGTGTGAGCTTTG-3′. The prim-
ers for the SNP 467 were 5′-AAGTTCACCTTCTCA-
AGC-3′ and 5′-TGAAAGAGTTTATTCTCTGG-3′ (Co-
hen et al. 1999). These primers amplified 429-bp,
430-bp, and 420-bp fragments for SNP 477, SNP 99217,
and SNP 467, respectively. PCR cycling conditions were
as follows: 94C for 4 min; followed by 28 cycles of
94C for 30 s, 55C for 30 s, and 72C for 20 s with a
final extension of 72C for 2 min, except annealing tem-
perature for SNP 477 was 60C. All PCR products were
purified using QuickStep PCR purification kit (Edge
BioSystems) to remove dNTPs and excess primers. All
sequencing reactions were performed using dye-termi-
nator chemistry (BigDye) and then were precipitated us-
ing 63%5% ethanol. Samples were loaded onto an
ABI 3700 DNAAnalyzer after adding 7 ml of formamide.
Mutation Screening
Probands from 92 families affected by HPC were
screened for sequence variations in the eight exons of
PG1 using SSCP analysis. All eight exons were screened
using 10 primer sets (see table 1) based on intronic se-
quence, as described by Cohen et al. (1999). Primers for
this analysis were chosen with a minimum distance of
4 bp between primer 3′ base and exon boundaries. Four
different electrophoresis and gel conditions were used to
maximize detection of sequence variations: mutation de-
tection enhancement (MDE) at room temperature,MDE
supplemented with 5% glycerol at room temperature,
MDE at 4C, and MDE supplemented with 5% glycerol
at 4C. SSCP gels were loaded immediately after com-
pletion of the PCR reactions incorporating 33P dATP,
then subjected to electrophoresis at 4 W for 16 h.
Fragment detection was accomplished by autoradiog-
raphy. Abnormally migrating products were directly se-
quenced as described above. Exons containing sequence
variations in HPC probands were analyzed in control
individuals as well.
Statistical Analyses
Tests for Hardy-Weinberg equilibrium (HWE) for all
the markers and for linkage disequilibrium (LD) between
all pairs of markers were performed using independent
individuals (pedigree founders and spouses of family
members) of families with HPC and all sporadic case
subjects and control subjects not affected with prostate
cancer (computer program GDA; Weir et al. 1996). The
HWE tests were based on exact tests, where a large num-
ber of the possible arrays was generated by permuting
the alleles among genotypes and the proportion of these
permuted genotypic arrays that have a smaller condi-
tional probability than the original data were calculated.
The LD tests were based on an exact test assuming mul-
tinominal probability of the multilocus genotype, con-
ditional on the single-locus genotype (Zaykin et al.
1995). A Monte Carlo simulation was used to assess the
significance, by permuting the single-locus genotypes
among individuals in the sample to simulate the null
distribution. The empirical P values of both the HWE
and LD tests were based on 10,000 replicate samples.
Multipoint linkage analyses were performed using
both parametric and nonparametric methods, imple-
mented by the computer program GENEHUNTER-
PLUS (Kruglyak et al. 1996; Kong and Cox 1997). For
the parametric analysis, the same autosomal dominant
model that was used by Smith et al. (1996) was assumed.
Under this model, disease-gene frequency of .003, in-
complete penetrance, and phenocopies were assumed.
Specifically, affected men were assumed to be disease-
gene carriers, with a fixed phenocopy rate of 15%,
whereas all unaffected men aged !75 years and all
women were assumed to be of unknown phenotype. In
men aged 75 years, the lifetime penetrance of gene
carriers was estimated to be 63%, and the lifetime risk
of prostate cancer for noncarriers was 16% in this age
class. Linkage in the presence of heterogeneity was as-
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sessed by use of Smith’s admixture test for heterogeneity
(Ott 1998). In this test, two types of families are as-
sumed, one type linked to the disease locus with a pro-
portion of a, and the other type is not linked, with the
proportion 1a. A maximum-likelihood approach was
used to estimate a by maximization of the admixed LOD
score (HLOD).
For the nonparametric analysis, the estimated marker
identical-by-descent (IBD) sharing of alleles for the var-
ious affected relative pairs was compared with its ex-
pected values under the null hypothesis of no linkage.
A statistic “Zall” in the program was used (Whittemore
and Halpern 1994). Allele-sharing LOD scores were
then calculated, on the basis of Zall, with equal weight
assigned to all families, using the computer program
ASM (Kong and Cox 1997).
Both HLOD and allele-sharing LOD can be converted
to a x2 ( # HLOD). Although the true distri-2x p 4.6
bution of the x2 under the null hypothesis of no linkage
is unknown—especially in multipoint analysis—we as-
sume that the distribution is a mixture of one that is
degenerate at 0 and one that can be approximated by
the distribution of the maximum of two independent x2
variables, each with 1 df (Faraway 1993). P values were
thus calculated by , where P10.5# [1 (1 P )(1 P )]1 1
is the P value of x2 with 1 df.
Family-based association tests were performed for all
six markers in the 159 families affected with HPC, using
a software package FBAT (Laird et al. 2000). Unlike the
classic transmission/disequilibrium test (TDT), which is
limited to a specific pedigree structure (one genotyped
proband and two genotyped parents per pedigree), the
FBAT utilizes data from nuclear families, sibships, or a
combination of the two to test for linkage and linkage
disequilibrium between traits and genotypes. The test
for linkage is valid when multiple affected members per
pedigree are used, and the power to detect linkage is
increased if there is an association. The test for associ-
ation is valid if one affected member per pedigree is used
(the genotypes of all the affected members can be in-
cluded) or if the empirical variance is used to account
for correlation between transmissions in families when
linkage is present. In brief, the FBAT determines, from
the data, an S statistic that is the linear combination of
offspring genotypes and phenotypes. The distribution of
the S statistic is generated by treating the offspring ge-
notype data as random and conditioning on the phe-
notypes and parental genotypes. When the marker is
biallelic, a Z statistic and its corresponding P value is
calculated. When the marker is multiallelic, a x2 test is
performed, with number of df equal to the number of
alleles.
Population-based association tests were performed for
the two polymorphisms in case and control subjects. An
unconditional logistic regression was used to test for
association between genotypes and affection status, ad-
justing for potential confounders such as age. The as-
sociation tests were also performed for whites only, to
decrease potential population stratification. The re-
ported P values were not adjusted for multiple testing.
Haplotype frequencies in unrelated individuals were
estimated for the three SNPs by maximum-likelihood
estimation, using the best state of haplotype composition
(see The Haplotype Estimation Help Page). The as-
sumption of equal prior probabilities was made as a
starting point for the expectation maximization (EM)
algorithm.
Results
Linkage Results at 8p22-23 in 159 Pedigrees Affected
by HPC
Both parametric and nonparametric multipoint link-
age analyses provided evidence for linkage between a
prostate cancer–susceptibility locus and markers on
chromosome 8p in the complete 159 HPC pedigrees (fig.
1). The highest parametric HLOD was 1.84 (Pp
) with , observed at D8S1130, 22 cM from.004 ap 0.14
8pter at 8p22. HLOD scores 0.5 extended across ∼22
cM, flanked by markers D8S1819 at 10 cM and
D8S1135 at 32 cM from 8pter. The number of pedigrees
that had LOD scores 10.3, 10.5, and 11 in the 22 cM
region were 66, 33, and 4, respectively. In the first 66
pedigrees that were included in our previous genome-
wide screen (Smith et al. 1996), the highest HLOD in-
creased from 0.7 at D8S550 (21 cM) to 1.67 (Pp
; ) at D8S1130 (22 cM), because of the.005 ap 0.24
inclusion of fine-mapping markers. The 93 new pedi-
grees also provided evidence for linkage, with the highest
HLOD of 0.77 ( ; ) at D8S552 (26 cM).Pp .06 ap 0.12
For the nonparametric analyses, the highest allele-shar-
ing LOD was 1.66 ( ) observed at D8S503, ∼16Pp .006
cM from 8pter in the complete family set. The highest
allele-sharing LODs were 1.99 ( ) at D8S1130Pp .002
and 0.34 ( ) at D8S552, respectively, in the firstPp .21
66 and new 93 pedigrees.
Linkage analyses stratified by pedigree characteristics
show that the pedigrees linked to 8p tend to have late
onset, larger numbers of affected family members, and
male-to-male disease transmission. Since the results from
parametric and nonparametric were similar, only the re-
sults from nonparametric analyses are presented (table
2). The peak allele-sharing LOD was 2.64 ( )Pp .0005
at D8S503 in the 79 pedigrees with mean age at onset
65 years, 1.41 ( ) at D8S503 in the 90 pedigreesPp .01
with five or more affected family members, and 1.31
( ) in the 99 pedigrees with male-to-male diseasePp .01
transmission. Evidence for linkage in this region was
observed in non-Jewish white pedigrees ( ) andnp 133
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Figure 1 Results of multipoint parametric and nonparametric linkage analyses of prostate cancer–susceptibility loci, using 24 markers
(21 microsatellite markers and 3 SNPs) on chromosome 8p22-23 in 159 families affected by HPC. The solid line represents parametric LOD
under the assumption of heterogeneity. The dotted line represents allele-sharing LOD. Each diamond and circle represents a marker.
in the 11 Ashkenazi Jewish pedigrees (2 from the first
66 families), but not in the 14 black pedigrees. It is worth
noting that 7 of the 11 Ashkenazi Jewish pedigrees had
LOD scores 0.3 in the region and that, as a group, the
11 Ashkenazi families contributed disproportionately to
the overall LOD score (table 2). By combining the non-
Jewish white pedigrees with Ashkenazi pedigrees, we ob-
served a LOD of 1.99 ( ) in the region.Pp .002
To evaluate the impact of the marker allele frequencies
on our linkage results in the black and Ashkenazi Jewish
families, we repeated linkage analyses for the 14 black
and 11 Ashkenazi families using marker allele frequen-
cies estimated from 19 unrelated blacks and 13 unrelated
Ashkenazi Jews, respectively. The results were similar to
that using marker allele frequencies estimated from the
mixed 214 unrelated subjects. In the 14 black families,
the peak HLOD changed from 0.26 to 0.1 at D8S261.
In the 11 Ashkenazi families, the peak HLOD changed
from 1.25 to 1.24 at D8S1135. The robustness of our
linkage results to the estimates of marker allele fre-
quencies is probably due to the use of dense markers in
multipoint analyses.
The evidence for linkage in and around the PG1 gene
(8 cM from pter) was weak. The highest HLOD and
allele sharing LOD was 0.35 ( ) and 0.32 (Pp .18 Pp
), respectively, in the five markers within and sur-.20
rounding the gene (from D8S277 to SNP 467).
Analysis of PG1: Family-Based Linkage and Association
Tests in 159 HPC Pedigrees
Tests for HWE were performed for all microsatellite
markers and SNPs analyzed, using 214 unrelated indi-
viduals from the 159 HPC pedigrees for which genotype
information was available. All the markers tested were
in HWE ( ). Marker-marker LD was tested for theP 1 .05
five closely spaced markers (SNPs) in the PG1 region.
Markers SNP 477, SNP 99217, D8S561, and SNP 467
were in strong LD, with for all pairwise tests.P ! .0001
Marker D8S277 was not in LD with these four markers
(SNPs).
Family-based linkage and association tests were per-
formed for the three SNPs. There was overtransmission
of allele T of SNP 99217 from parents to affected sons,
with ( ). The observed score Swas 151Zp 2.19 Pp .03
for allele T, compared with the expected 139. Similar
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Table 2
Nonparametric Allele-Sharing LOD
MARKERS cMa
NONPARAMETRIC ALLELE-SHARING LOD
Age at Onset
No. of Affected
Subjects
Male-to-Male
Transmission Ethnicity
!65
( )np 79
65
( )np 80
!5
( )np 69
5
( )np 90
Yes
( )np 99
No
( )np 60
Black
( )np 14
Ashkenazi
( )np 11
Non-Jewish
White
( )np 133
D8S504 0 0 .44 .00 .11 .2 0 0 .67 0
D8S262 4.3 0 .67 .00 .36 .11 .02 0 .78 .13
D8S518 5.6 0 .75 .00 .43 .15 .03 0 .93 .18
D8S1798 6.7 0 .91 .00 .43 .17 .04 0 1.01 .16
D8S277 8.2 0 1.01 .00 .52 .14 .09 0 .92 .18
SNP 477 8.3 0 1 .00 .55 .16 .09 0 .92 .19
SNP 99217 8.4 0 1.02 .00 .59 .18 .09 0 .92 .2
D8S561 8.5 0 .99 .00 .58 .17 .09 0 .92 .2
SNP 467 8.6 0 1.13 .00 .6 .24 .09 0 .92 .2
D8S1819 10 0 1.58 .00 .89 .47 .14 0 .93 .45
D8S1706 10.5 0 1.64 .00 .88 .58 .09 0 .96 .47
D8S503 16.2 0 2.64 .31 1.41 1.31 .39 0 1.27 1.38
D8S516 17 0 2.64 .24 1.41 1.16 .42 0 1.3 1.28
D8S542 17.5 0 2.61 .19 1.38 .98 .48 0 1.31 1.18
D8S550 21.3 0 1.96 .12 1.03 .69 .35 0 1.3 .81
D8S265 21.9 0 1.89 .13 1.17 .85 .34 0 1.26 .91
D8S1130 22.4 .1 1.97 .15 1.67 1.07 .56 0 1.12 1.39
D8S552 26.4 0 2.32 .28 1.09 .79 .54 0 .92 1.11
D8S1106 26.5 0 2.32 .28 1.09 .8 .54 0 .93 1.12
D8S1109 27.8 0 1.97 .11 1.03 .71 .33 0 1.07 .82
D8S1827 30.5 0 1.56 .01 .9 .84 .02 0 1.27 .36
D8S1731 31.7 0 1.55 .00 1.09 .9 0 0 1.51 .28
D8S1135 32.7 0 1.35 .00 1.13 .8 .02 0 1.6 .31
D8S261 37 0 .62 .00 .41 .11 .01 0 .85 .02
a Based on the Marshfield map.
tests for SNP 477 and SNP 467 were not significant,
with ( ) and ( ), re-Zp 0.85 Pp .40 Zp 0.31 Pp .76
spectively. To decrease the impact of heterogeneity
among races, the family-based linkage and association
tests were performed again in the 133 non-Jewish white
pedigrees. The test for SNP 99217 was significant, with
( ). The tests for the other two SNPsZp 2.70 Pp .007
were not significant.
As either linkage or association in the data may lead
to the significant test statistics, we performed two ad-
ditional analyses to further explore the finding. The first
analysis was a family-based association test using the
empirical variance to account for correlation between
transmissions in families when linkage is present. In this
analysis, the evidence for association decreased, with
( ) and ( ), respec-Zp 1.66 Pp .10 Zp 2.07 Pp .04
tively in the complete 159 HPC pedigrees and in 133
non-Jewish white pedigrees. The second analysis is the
stratified linkage analyses based on the probands’ ge-
notype at SNP 99217. The pedigrees whose probands
are T carriers contributed disproportionally to the evi-
dence for linkage at 5 markers in the region. The 77
pedigrees whose probands are heterozygous ‘T’ and the
15 pedigrees whose probands are homozygous ‘T’ car-
riers had allele-sharing LODs of 0.5 ( ) and 1.44Pp .12
( ) at SNP 99217, respectively. In contrast, thePp .01
78 pedigrees whose probands are not T carriers had
HLOD of 0. These data suggest that both linkage and
association contribute to the significance of the family-
based test.
Analysis of PG1: Population-Based Association Tests in
HPC Probands, Unrelated Case Subjects, and
Unaffected Control Subjects
The three PG1 SNPs were genotyped in all 159 HPC
pedigrees and in 249 unrelated prostate cancer case sub-
jects and 211 unaffected control subjects. All SNPs were
in HWE in each subset. Allele frequencies of the three
SNPs were compared between case and control subjects.
To decrease the confounding factor of racial differences,
the comparison was limited to whites only. For SNP 477,
the allele frequencies of G were 0.33, 0.33, and 0.31, in
the 123 HPC probands, 216 unrelated case subjects, and
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Table 3
Genotypes of Three SNPs in PG1 in Probands, Unrelated Case Subjects, and Unaffected Control Subjects (White Subjects Only)
SNP AND
GENOTYPE
CONTROL
SUBJECTS
(%)
CASE SUBJECTS (%) ODDS RATIOa (95% CI)
Sporadic HPC
Sporadic Case Subjects
vs. Control Subjects
HPC Case Subjects vs.
Control Subjects
All Case Subjects vs.
Control Subjects
SNP 477: np178 np222 np123
C/C .47 .46 .46 1 1 1
C/G .44 .41 .42 1.06 (.70–1.60) .96 (.59–1.58) 1.03 (.70–1.51)
G/G .09 .13 .12 1.38 (.69–2.74) 1.36 (.61–3.04) 1.39 (.73–2.63)
Any G 1.11 (.75–1.65) 1.03 (.64–1.64) 1.09 (.76–1.57)
SNP 99217: np177 np217 np131
C/C .49 .51 .47 1 1 1
C/T .42 .36 .41 .97 (.64–1.48) .99 (.61–1.61) .99 (.67–1.44)
T/T .08 .13 .11 1.20 (.59–2.45) 1.33 (.60–2.97) 1.25 (.65–2.41)
Any T 1.01 (.68–1.51) 1.05 (.66–1.67) 1.03 (.72–1.48)
SNP 467: np177 np212 np120
G/G .59 .59 .60 1 1 1
G/A .34 .32 .32 1.10 (.72–1.69) .92 (.55–1.54) 1.03 (.69–1.53)
A/A .07 .10 .08 1.30 (.60–2.84) 1.20 (.49–2.93) 1.28 (.63–2.63)
Any A 1.14 (.76–1.71) .97 (.60–1.57) 1.08 (.74–1.56)
a All odds ratios were adjusted for age.
178 unaffected control subjects, respectively. For SNP
99217, the allele frequencies of T were 0.32, 0.31, and
0.30, in the 131 HPC probands, 222 unrelated case sub-
jects, and 177 unaffected control subjects, respectively.
For SNP 467, the allele frequencies of A were 0.24, 0.25,
and 0.24, in the 120 HPC probands, 210 unrelated case
subjects, and 177 unaffected control subjects, respec-
tively. No significant difference was observed in the allele
frequencies between the probands and control subjects,
between the unrelated case subjects and control subjects,
or between all case subjects and control subjects in any
of the three SNPs.
Genotype frequencies of the three SNPs were also
compared in the white subjects only (table 3). No sta-
tistical differences in genotype frequencies were observed
between case and control subjects for any of the three
SNPs. There was a trend toward higher homozygous
rates of the less-frequent alleles of each SNP in the case
subjects with HPC and in the unrelated case subjects,
compared with those in the control subjects; however,
the differences were not statistically significant. For ex-
ample, the odds ratio (OR) was 1.39 (95% confidence
interval [CI] 0.73–2.63) when the homozygous frequen-
cies for T/T of SNP 477 in all case and control subjects
were compared.
Haplotype frequencies of the three SNPs were also
compared between case and control subjects. The esti-
mated haplotype frequencies of G-T-A for the three SNPs
(SNP 477, SNP 99217, and SNP 467) were 0.21, 0.25,
and 0.22, in HPC probands, unrelated case subjects, and
unaffected control subjects, respectively. No significant
statistical differences in the haplotype frequencies were
found between all possible pair comparisons.
Mutation Screening of PG1
SSCP mutation-screening analysis of probands from
92 families with HPC produced band patterns indicative
of two different sequence variants in exon 1 and three
different variants in exon 4. For exon 1, sequence anal-
ysis identified one variant as a silent polymorphism
(CrG at codon 43, position 2159 in the genomic se-
quence reported by Cohen et al. [1999]), which was
present in 14.1% of probands and in 7.9% of unaffected
control subjects. The other variant was a nonsynony-
mous change at codon 22 (GrC at position 2095, re-
sulting in substituting Ala for Gly), present in 4.2% of
probands and 2.2% of control subjects.
Sequence analysis of the variants in exon 4 demon-
strated two silent polymorphisms (TrC in codon 145
at position 25631 in the genomic sequence reported by
Cohen et al. [1999], and ArG in codon 139 at position
25615) and a nonsynonymous change at position 25649
(GrA resulting in a substitution of Thr for Ala at codon
151). These variants were present at low frequencies
(0.5%–3%) with no differences between case and con-
trol subjects (e.g., the AlarThr change was observed in
one proband, one sporadic case subject, and one control
individual).
Discussion
By testing for linkage and association between prostate
cancer susceptibility and markers on 8p22-23 in 159
HPC pedigrees, 249 unrelated case subjects, and 211
unaffected control subjects, we obtained the following
three findings. (1) There was evidence for linkage be-
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tween a prostate cancer–susceptibility locus andmarkers
on 8p22-23, with a highest HLOD of 1.84 ( )Pp .004
at D8S1130. The region providing evidence for linkage
spanned ∼22 cM at 8p22-23. The evidence for linkage
was observed in the first 66 HPC pedigrees and in the
93 new HPC pedigrees. The pedigrees with late age at
onset, a large number of affected family members, and
male-to-male disease transmission provided stronger ev-
idence for linkage at the region. (2) One intronic se-
quence variant (allele T of SNP 99217) in the putative
prostate cancer–susceptibility gene (PG1) was overtrans-
mitted from parents to affected offspring, with Zp
( ) and ( ) in all 1592.19 Pp .03 Zp 2.70 Pp .007
HPC pedigrees and in 133 non-Jewish white pedigrees,
respectively. The overtransmission of allele T likely re-
flected evidence for both linkage and association in the
data, since (a) a family-based association test that ac-
counted for the presence of linkage provided weaker but
still marginally significant test statistics, with Zp
( ) and 2.07 ( ) in all HPC pedigrees1.66 Pp .10 Pp .04
and in non-Jewish white pedigrees, and (b) families
whose probands carry T are more likely to be linked to
the PG1 gene region. (3) No statistical differences were
found in the allele, genotype, and haplotype frequencies
for the three SNPs or other sequence variants in the PG1
gene between HPC probands, unrelated prostate cancer
case subjects, and unaffected control subjects. However,
a trend (but not a statistically significant one) was ob-
served toward higher homozygous rates of the less-fre-
quent allele of each SNP in the HPC case subjects and
in the unrelated case subjects, compared with those
among the control subjects.
Evidence for linkage at 8p22-23 in our study did not
reach the genomewide screen criteria for significant or
suggestive linkage as proposed by Lander and Kruglyak
(1995). However, we think our results provide a basis
for further study in this region for a number of reasons.
First, the prior probability that a prostate can-
cer–susceptibility gene lies near 8p22-23 is high as ex-
tensive evidence from LOH studies in prostate and other
cancers indicates the existence of tumor-suppressor
genes in the region (for review, see work by Bookstein
[2001]). Therefore, the stringent criterion for significant
linkage, which is used to account for the low prior prob-
ability of any pair of genes being located within a re-
combination fraction of !.5 in the human genome, is
not appropriate in this situation (Ott 1998). Secondly,
although the HLOD of 1.84 ( ) could representPp .004
false-positive evidence for linkage, our simulation re-
sults suggested that it is unlikely. On the basis of the
same structure of 159 pedigrees with HPC (affection
status and availability of genotyping) and the genetic
model used in the analyses, we simulated 10,000 rep-
licates with a six-allele marker (equally frequent) not
linked to the disease gene using FASTSLINK (see D.
Weeks’s FTP page). We then analyzed each replicate and
only observed 10 of the 10,000 replicates with a HLOD
11.84, yielding an empirical P value of .001. Thirdly,
and perhaps most importantly, the same region was re-
ported to be linked to a prostate cancer–susceptibility
gene in an independent genomewide-screen linkage
study. Gibbs et al. (2000) reported a maximum multi-
point nonparametric linkage score of 2.02 at D8S1106
in 44 pedigrees with late age at onset (66 years), using
genomewide screen markers. This marker was in our
linkage region, ∼5 cM from the peak marker, D8S1130.
Interestingly, we observed the same trend that pedigrees
with late age at onset tend to be linked to this region,
with a peak allele sharing LOD of 2.64 ( ) inPp .0005
our 80 pedigrees with age at onset 65 years. Lastly,
both series of our HPC pedigrees (the first 66 HPC
pedigrees included in the initial genomewide screen and
the 93 pedigrees ascertained later) provided evidence
for linkage. The trend for this linkage to be more prom-
inent in families with older age at diagnosis was ob-
served in both the first and the second groups of families
(allele-sharing LOD scores of 1.46, and 1.32,Pp .009
respectively).Pp .01
Even though some evidence for linkage at the PG1
gene was observed in parametric and nonparametric
linkage analyses and family-based linkage and associ-
ation test, the rather weak linkage at PG1 gene and the
distance (10–15 cM) between the PG1 gene and the
highest linkage region indicated that the PG1 plays a
minor role, if any, in accounting for the linkage signal
at 8p22-23. One or several other genes in the region
may contribute to the observed linkage. Several impor-
tant candidate tumor-suppressor genes reside in the
8p22-23 region, including the N33 (Bova et al. 1996),
macrophage-scavenger-receptor (MSR) (Kagan et al.
1995; Bova et al. 1996), the N-acetyltransferase genes
NAT1 and NAT2 (Wang et al. 1999), LZTS1 (Ishii et
al. 1999), and DLC1 (deleted in liver cancer; see Yuan
et al. 1998; Wilson et al. 2000). Several mutations in
LZTS1 were found in prostate cancer cell lines. Tran-
script analysis from several LZTS1-expressing tumors
revealed truncated mRNAs, including a frameshift (Ishii
et al. 1999). Mutations in DLC1 were found in colo-
rectal and ovarian tumors (Wilson et al. 2000). Unfor-
tunately, studies investigating possible associations be-
tween the genomic sequence variants and prostate
cancer have not been published.
The interpretation of the results from our PG1
gene–association study is difficult. Although overtrans-
mission of allele T of SNP 99217 from parents to af-
fected offspring provides evidence that PG1 might in-
fluence prostate cancer susceptibility, the lack of
statistically significant differences in the allele, geno-
type, and haplotype frequencies between case and con-
trol subjects is not consistent with this notion. Our re-
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sults contrast with the results from the case-control
study reported by Cohen et al. (1999). Although the
exact reason for the difference is unknown, several of
the following factors may contribute to the difference.
First, there may be allele-frequency differences between
the French and U.S. populations, and the former may
be a more homogeneous population. This is, however,
unlikely to be the major reason in this case, because the
allele frequencies in the case subjects are similar in the
two populations. Second, the power to detect the as-
sociation in our study sample is limited. Using the point
estimates of ORs and frequencies from Cohen et al.
(1999), the power to detect an OR of 2.2, at the sig-
nificance level of .05, with a genotype frequency of 14%
in control subjects, is 72% in our combined 345 case
and 177 control samples (white subjects only). Third,
potential misclassification may be present in our control
group. Although the unaffected control subjects in our
study had normal results on digital rectal examination
and normal PSA levels (i.e., !4 ng/ml), some of our
control subjects are young, and they could be disease-
gene carriers who will develop prostate cancer later. The
ORs adjusted for age in our study may alleviate the
problem but cannot remove the confounder. Last, ran-
dom sampling error in control subjects in both studies
could lead to the difference. In consideration of the lim-
ited power to detect a weak association and potential
bias in the study, further studies utilizing larger number
of control subjects may help to answer the question.
In summary, our study provides evidence for prostate
cancer linkage at 8p22-23. The linkage results, along
with the consistent evidence that 8p22 is the most com-
monly deleted region in prostate cancer cells and the
discovery of mutations in some tumor-suppressor genes
in the region warrant further studies. The results of the
evaluation of the PG1 gene are inconclusive but inter-
esting enough to suggest further studies of this gene as
well. With the availability of more-complete sequence
data for the human genome, studies to systematically
evaluate all the genes in the region using an association
study design (either case-control or family-based) are
justified and likely to succeed.
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